Rituximab reduces the incidence of acute graft-versus-host disease.

Christopeit, Maximilian; Schütte, Vincent; Theurich, Sebastian; Weber, Thomas; Grothe, Wilfried; Behre, Gerhard

Christopeit, Maximilian; Schütte, Vincent; Theurich, Sebastian; Weber, Thomas; Grothe, Wilfried; Behre, Gerhard.

Blood ; 113(13): 3130-1, 2009 Mar 26.

Article in En | MEDLINE | ID: mdl-19324911

Subject(s)

Antibodies, Monoclonal/therapeutic use; Graft vs Host Disease/epidemiology; Graft vs Host Disease/prevention & control; Lymphoma, Non-Hodgkin/therapy; Acute Disease; Adult; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum/therapeutic use; Female; Humans; Immunologic Factors/therapeutic use; Immunotherapy/methods; Incidence; Leukemia/immunology; Leukemia/therapy; Lymphoma, Non-Hodgkin/immunology; Male; Retrospective Studies; Rituximab; Stem Cell Transplantation; Transplantation Conditioning/methods

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Graft vs Host Disease / Antibodies, Monoclonal Type of study: Evaluation_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Journal: Blood Year: 2009 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google